| References |
Top |
| REF 1 |
Expression of the nuclear factor-B inhibitor A20 is altered in the cystic fibrosis epithelium. Eur Respir J. 2013 Jun;41(6):1315-23.
|
| REF 2 |
Lys11-linked ubiquitin chains adopt compact conformations and are preferentially hydrolyzed by the deubiquitinase Cezanne. Nat Struct Mol Biol. 2010 Aug;17(8):939-47.
|
| REF 3 |
Molecular basis for the unique deubiquitinating activity of the NF-kappaB inhibitor A20. J Mol Biol. 2008 Feb 15;376(2):526-40.
|
| REF 4 |
The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol. 2004 Oct;5(10):1052-60.
|
| REF 5 |
Direct and indirect control of mitogen-activated protein kinase pathway-associated components, BRAP/IMP E3 ubiquitin ligase and CRAF/RAF1 kinase, by the deubiquitylating enzyme USP15. J Biol Chem. 2012 Dec 14;287(51):43007-18.
|
| REF 6 |
YOD1/TRAF6 association balances p62-dependent IL-1 signaling to NF-B. Elife. 2017 Feb 28;6. pii: e22416.
|
| REF 7 |
The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation. Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6721-5.
|
| REF 8 |
Involvement of A20 in the molecular switch that activates the non-canonical NF-B pathway. Sci Rep. 2013;3:2568.
|
| REF 9 |
The A20 protein interacts with the Epstein-Barr virus latent membrane protein 1 (LMP1) and alters the LMP1/TRAF1/TRADD complex. Virology. 1999 Nov 10;264(1):159-66.
|
| REF 10 |
A proteome-scale map of the human interactome network. Cell. 2014 Nov 20;159(5):1212-1226.
|
| REF 11 |
Architecture of the human interactome defines protein communities and disease networks. Nature. 2017 May 25;545(7655):505-509.
|
| REF 12 |
The RING ubiquitin E3 RNF114 interacts with A20 and modulates NF-B activity and T-cell activation. Cell Death Dis. 2014 Aug 28;5:e1399.
|
| REF 13 |
A20 inhibits LUBAC-mediated NF-B activation by binding linear polyubiquitin chains via its zinc finger 7. EMBO J. 2012 Oct 3;31(19):3845-55.
|
| REF 14 |
14-3-3 proteins associate with A20 in an isoform-specific manner and function both as chaperone and adapter molecules. J Biol Chem. 1996 Aug 16;271(33):20029-34.
|
| REF 15 |
A20 inhibits NF-kappaB activation independently of binding to 14-3-3 proteins. Biochem Biophys Res Commun. 1997 Sep 18;238(2):590-4.
|
| REF 16 |
Toward an understanding of the protein interaction network of the human liver. Mol Syst Biol. 2011 Oct 11;7:536.
|
| REF 17 |
TNFAIP3 promotes survival of CD4 T cells by restricting MTOR and promoting autophagy. Autophagy. 2015;11(7):1052-62.
|
| REF 18 |
TNFAIP3-DEPTOR complex regulates inflammasome secretion through autophagy in ankylosing spondylitis monocytes. Autophagy. 2018;14(9):1629-1643.
|
| REF 19 |
De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature. 2004 Aug 5;430(7000):694-9.
|
| REF 20 |
A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov. 2012 Feb;2(2):140-55.
|
| REF 21 |
Endotoxin tolerance impairs IL-1 receptor-associated kinase (IRAK) 4 and TGF-beta-activated kinase 1 activation, K63-linked polyubiquitination and assembly of IRAK1, TNF receptor-associated factor 6, and IkappaB kinase gamma and increases A20 expression. J Biol Chem. 2011 Mar 11;286(10):7905-16.
|
| REF 22 |
A20 inhibits NF-kappa B activation downstream of multiple Map3 kinases and interacts with the I kappa B signalosome. Cytokine. 2001 Sep 21;15(6):282-98.
|
| REF 23 |
Defining the human deubiquitinating enzyme interaction landscape. Cell. 2009 Jul 23;138(2):389-403.
|
| REF 24 |
ABIN1 protein cooperates with TAX1BP1 and A20 proteins to inhibit antiviral signaling. J Biol Chem. 2011 Oct 21;286(42):36592-602.
|
| REF 25 |
Pathogen-induced ubiquitin-editing enzyme A20 bifunctionally shuts off NF-B and caspase-8-dependent apoptotic cell death. Cell Death Differ. 2017 Sep;24(9):1621-1631.
|
| REF 26 |
Bladder polypoid cystitis-derived A20 associates with tumorigenesis. Cell Biochem Biophys. 2013 Nov;67(2):669-73.
|
| REF 27 |
Ubiquitin ligase A20 regulates p53 protein in human colon epithelial cells. J Biomed Sci. 2013 Oct 7;20:74.
|
| REF 28 |
Involvement of Ymer in suppression of NF-kappaB activation by regulated interaction with lysine-63-linked polyubiquitin chain. Biochim Biophys Acta. 2008 May;1783(5):826-37.
|
| REF 29 |
Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep. 2009 May;10(5):466-73.
|
| REF 30 |
OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis. Cell. 2013 Jul 3;154(1):169-84.
|
| REF 31 |
Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J. 2004 Mar 15;378(Pt 3):727-34.
|
| REF 32 |
Ubiquitin binding to A20 ZnF4 is required for modulation of NF-B signaling. Mol Cell. 2010 Nov 24;40(4):548-57.
|
| REF 33 |
Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-B regulation. EMBO J. 2012 Oct 3;31(19):3856-70.
|
| REF 34 |
Molecular basis of Lys11-polyubiquitin specificity in the deubiquitinase Cezanne. Nature. 2016 Oct 20;538(7625):402-405.
|
| REF 35 |
Direct, noncatalytic mechanism of IKK inhibition by A20. Mol Cell. 2011 Nov 18;44(4):559-71.
|
| REF 36 |
The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN. J Cell Biol. 1999 Jun 28;145(7):1471-82.
|
| REF 37 |
Functional redundancy of the zinc fingers of A20 for inhibition of NF-kappaB activation and protein-protein interactions. FEBS Lett. 2001 Jun 1;498(1):93-7.
|
| REF 38 |
Structure-function analysis of the A20-binding inhibitor of NF-kappa B activation, ABIN-1. FEBS Lett. 2003 Feb 11;536(1-3):135-40.
|
| REF 39 |
The zinc finger protein A20 interacts with a novel anti-apoptotic protein which is cleaved by specific caspases. Oncogene. 1999 Jul 22;18(29):4182-90.
|
| REF 40 |
Identification of a novel A20-binding inhibitor of nuclear factor-kappa B activation termed ABIN-2. J Biol Chem. 2001 Aug 10;276(32):30216-23.
|
| REF 41 |
A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma. Clin Cancer Res. 2011 Mar 15;17(6):1440-51.
|
| REF 42 |
SPATA2 links CYLD to the TNF- receptor signaling complex and modulates the receptor signaling outcomes. EMBO J. 2016 Sep 1;35(17):1868-84.
|
| REF 43 |
LIND/ABIN-3 is a novel lipopolysaccharide-inducible inhibitor of NF-kappaB activation. J Biol Chem. 2007 Jan 5;282(1):81-90.
|
